Oxford Asset Management’s Cidara Therapeutics CDTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-8,357
| Closed | -$1.85M | – | 522 |
|
|
2025
Q4 | $1.85M | Buy |
+8,357
| New | +$1.35M | 0.65% | 22 |
|
|
2020
Q1 | $144K | Sell |
2,911
-5,652
| -66% | -$339K | 0.02% | 129 |
|
|
2019
Q4 | $658K | Buy |
+8,563
| New | +$392K | 0.02% | 1092 |
|
|
2019
Q2 | – | Sell |
-4,852
| Closed | -$257K | – | 1726 |
|
|
2019
Q1 | $257K | Sell |
4,852
-1,326
| -21% | -$72.7K | 0.01% | 1446 |
|
|
2018
Q4 | $290K | Buy |
6,178
+2,104
| +52% | +$150K | 0.01% | 1416 |
|
|
2018
Q3 | $362K | Buy |
4,074
+1,820
| +81% | +$161K | 0.01% | 1433 |
|
|
2018
Q2 | $234K | Sell |
2,254
-1,558
| -41% | -$147K | ﹤0.01% | 1554 |
|
|
2018
Q1 | $305K | Buy |
3,812
+2,363
| +163% | +$323K | 0.01% | 1403 |
|
|
2017
Q4 | $196K | Buy |
1,449
+340
| +31% | +$51.6K | ﹤0.01% | 1460 |
|
|
2017
Q3 | $187K | Buy |
1,109
+453
| +69% | +$64.4K | ﹤0.01% | 1432 |
|
|
2017
Q2 | $98K | Buy |
+656
| New | +$90.7K | ﹤0.01% | 1412 |
|
|
2017
Q1 | – | Sell |
-641
| Closed | -$133K | – | 1398 |
|
|
2016
Q4 | $133K | Buy |
+641
| New | +$133K | ﹤0.01% | 725 |
|
Oxford Asset Management's CDTX Position: Q1 2026 in Review
Oxford Asset Management sold out of Cidara Therapeutics (CDTX) in Q1 2026, closing a stake of 8,357 shares — an estimated $1.85M sold.
Oxford Asset Management first reported a position in CDTX in Q4 2016 and held it in 12 quarters. The position peaked at $1.85M in Q4 2025. 0 funds tracked by Wall St. Rank hold CDTX as of Q1 2026.
- Oxford Asset Management reported no remaining Cidara Therapeutics position as of Q1 2026 after selling out during the quarter.
- Oxford Asset Management sold 8,357 Cidara Therapeutics shares in Q1 2026, an estimated $1.85M.
- Oxford Asset Management first reported a position in Cidara Therapeutics in Q4 2016 and held it in 12 quarters.
- Oxford Asset Management's Cidara Therapeutics position peaked at $1.85M in Q4 2025.
- 0 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q1 2026.
Based on Oxford Asset Management's 13F filing for Q1 2026, filed 15 May 2026.